Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Cash & Equivalents: 2020-2022

Historic Cash & Equivalents for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2022 value amounting to $156.2 million.

  • Cullinan Therapeutics' Cash & Equivalents fell 19.03% to $466.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $466.4 million, marking a year-over-year decrease of 19.03%. This contributed to the annual value of $156.2 million for FY2022, which is 161.24% up from last year.
  • According to the latest figures from FY2022, Cullinan Therapeutics' Cash & Equivalents is $156.2 million, which was up 161.24% from $59.8 million recorded in FY2021.
  • In the past 5 years, Cullinan Therapeutics' Cash & Equivalents registered a high of $168.2 million during FY2020, and its lowest value of $59.8 million during FY2021.
  • Moreover, its 3-year median value for Cash & Equivalents was $156.2 million (2022), whereas its average is $128.0 million.
  • As far as peak fluctuations go, Cullinan Therapeutics' Cash & Equivalents tumbled by 64.46% in 2021, and later soared by 161.24% in 2022.
  • Cullinan Therapeutics' Cash & Equivalents (Yearly) stood at $168.2 million in 2020, then tumbled by 64.46% to $59.8 million in 2021, then surged by 161.24% to $156.2 million in 2022.